Tropicamide/phenylephrine

Tropicamide/phenylephrine, sold under the brand name Mydcombi is a fixed dose combination of tropicamide and phenylephrine used to dilate the eyes (mydriasis).[1] It contains, tropicamide, an anticholinergic, and phenylephrine, as the hydrochloride, an alpha-1 adrenergic receptor agonist.[1] It is sprayed into the eyes.[1]

Tropicamide/phenylephrine
Combination of
TropicamideAnticholinergic
PhenylephrineAlpha-1 adrenergic receptor agonist
Clinical data
Trade namesMydcombi
Routes of
administration		Topical, ophthalmic
ATC code
Legal status
Legal status

It was approved for medical use in the United States in May 2023.[2][3]

Medical uses

Tropicamide/phenylephrine is used for the short-term dilation of the pupils.[1]

References
  1. https://mydcombi.com/wp-content/uploads/2023/05/MydCombi-PI-05072023.pdf
  2. "Mydcombi: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 8 May 2023.
  3. "Eyenovia Announces FDA Approval of Mydcombi, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company's Proprietary Optejet Device Platform". Eyenovia. 8 May 2023. Retrieved 8 May 2023.
  • Clinical trial number NCT03751631 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-1)" at ClinicalTrials.gov
  • Clinical trial number NCT03751098 for "Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation (MIST-2)" at ClinicalTrials.gov


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.